Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine/cyclophosphamide with or without rituximab for untreated mantle cell lymphoma
ISRCTN81133184Phase 2Completed
- Sponsor
- University College London
- Start
- Oct 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in mantle cell lymphoma (MCL) comparing Fludarabine + cyclophosphamide with Rituximab + fludarabine + cyclophosphamide (2 arms). Primary endpoints: Response rate, Time to disease progression and 2 more. Started Oct 2002; status: completed.
02
Drugs
fludarabinecyclophosphamiderituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ISRCTN81133184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN81133184.